BB
Therapeutic Areas
Editas Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EDIT-401 | Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD) | Pre-clinical |
| Undisclosed In Vivo Program | Sickle Cell Disease (SCD) | Research |
| Alpha-beta T-cell medicines | Oncology | Undisclosed |
| Gamma-delta T-cell medicines | Oncology | Undisclosed |
Leadership Team at Editas Medicine
GO
Gilmore O’Neill
President and Chief Executive Officer
LC
Linda C. Burkly
Executive Vice President and Chief Scientific Officer
DG
Damien Grierson
Senior Vice President and General Counsel
FP
Frank Panaccio
Senior Vice President and Chief Business Officer
AP
Amy Parison
Senior Vice President and Chief Financial Officer
GW
Gregory Whitehead
Executive Vice President and Chief Technical and Quality Officer